Haemonetics

HAE · NYSE

$118.21−$0.52 (−0.44%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $118.73

HAE analyst rating

BuyConsensus of 10 analysts over the last 12 months. 70% rate it a buy.

Strong buy0
Buy7
Hold3
Underperform0
Sell0

12-month price target · 11 analysts

Average $116.62 (−1.3% downside)

Low: $95.95
Now: $118.21
High: $131.25

Upgrades and downgrades

The latest rating actions, newest first

HAE analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Barrington Research	Oct 9, 2026	Maintains	Outperform	$118.00 → $140.00	44%
Mizuho	Oct 9, 2026	Maintains	Outperform	$95.00 → $140.00	56%
BTIG	Oct 8, 2026	Maintains	Buy	$110.00 → $130.00	56%
Citigroup	Sep 17, 2026	Upgrade	Neutral → Buy	$92.00 → $123.00	60%
Raymond James	Sep 3, 2026	Maintains	Outperform	$105.00 → $125.00	44%
Baird	Aug 21, 2026	Maintains	Outperform	$96.00 → $119.00	64%
Barrington Research	Aug 19, 2026	Maintains	Outperform	$95.00 → $118.00	44%
BTIG	Aug 18, 2026	Maintains	Buy	$96.00 → $110.00	56%
Citigroup	Aug 7, 2026	Maintains	Neutral	$79.00 → $92.00	60%
JP Morgan	Aug 7, 2026	Maintains	Neutral	$62.00 → $86.00	31%

The case for and against

Updated Oct 14, 2026

Bull case

Haemonetics is supported by a stronger Plasma outlook, as the CSL Plasma agreement could extend NexSys PCS devices and Persona PLUS technology across all current U.S. collection centers by end of calendar year 2027, helping recapture share and reduce fears of future market loss. The company also showed broad operational momentum in F1Q, with revenue of $339.4M, adj. EPS of $1.14, Plasma sales of $155.5M, and double-digit growth in key disposables, while guidance was raised to 5%-8% reported revenue growth and 4%-7% organic growth for FY2027. In addition, higher-margin Hospital and Plasma exposure, improving operating margins, and a return to growth in Interventional Technologies support the view that profitability and earnings power can continue expanding.

Bear case

Haemonetics is viewed negatively because its revenue base remains vulnerable to customer concentration, with CSL Plasma representing about 13% of FY24 net revenues and previously signaling non-renewal of PCS 2 systems and disposable kit purchases, which triggered major investor concern about sales and earnings durability. Although the amended agreement now runs through December 2025 and includes at least $85M of FY25 minimum purchases, the fact that CSL Plasma’s U.S. centers have shifted to competitor Terumo and that only European centers use NexSys PCS highlights continuing competitive pressure in Plasma. The company also faces execution risk across Interventional Technologies, uncertain procedure volumes, and broader threats from recombinant therapies, tariffs, and cybersecurity, making the earnings outlook fragile despite solid margins and brand strength.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.